ReviewCancer reports (Hoboken, N.J.)2026
Ten-Year Outcome of a Patient With Concurrent Pelvic Myeloid Sarcoma and Underlying Chronic Myeloid Leukaemia in Chronic Phase: A Case Report and Literature Review.
Review in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyeloid sarcoma is a rare solid tumour of immature myeloid precursors occurring in an extramedullary site. It often presents significant diagnostic and therapeutic challenges to clinical haematologists. CASE: We describe a previously healthy patient who presented simultaneously with hyperleucocytic chronic myeloid leukaemia in chronic phase (CML-CP) and a pelvic myeloid sarcoma (MS). She failed to respond to conventional intensive chemotherapy meant for acute myeloid leukaemia but responded well to a combination of radiotherapy and tyrosine kinase inhibitor. She has remained well and in deep molecular response for the past 10 years.
conclusionWe report the first case of MS in CML-CP that has achieved 10 years of long-term remission with a combination of radiotherapy and tyrosine kinase inhibitor, without allogeneic stem cell transplantation. We also reviewed the literature on CML-CP with simultaneous MS to determine the disease characteristics and treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.